RxDoctor Payments Data

Frances Rosario

Family · Albany, NYNPI 1679956643

Payments from drug & device makers

$374in general payments, 2019–2025

Across 19 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$78
  • Pfizer$38
  • Indivior Inc.$35
  • Novo Nordisk$32
  • Astellas Pharma US Inc$31
  • Collegium Pharmaceutical, Inc.$24
  • plus $135 from 8 others

What the payments were for

  • Food & beverage$374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$374 in reported general payments places this provider in the 50th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$27,644
Medicare patients
138
Services billed
599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$58,799
JardianceEmpagliflozin42$44,461
JanuviaSitagliptin Phosphate18$26,667
TrulicityDulaglutide25$24,157
OzempicSemaglutide19$17,688
EliquisApixaban17$13,874
FarxigaDapagliflozin Propanediol19$12,762
TradjentaLinagliptin13$12,632
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$12,137
Incruse ElliptaUmeclidinium Bromide24$9,434
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$8,604
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$6,512
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$5,674
SymbicortBudesonide/Formoterol Fumarate33$5,613
OxycontinOxycodone Hcl12$5,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$16$80,370123 claims
MerckJanuvia$15$26,66718 claims
Lilly USA, LLCTrulicity$17$24,15725 claims
Novo NordiskOzempic$32$17,68819 claims
PfizerEliquis$38$13,87417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,883 family providers in New York.

Other family in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →